Related Experiment Video
Updated: Jun 14, 2026

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL
Sanjib Dutta1, Stefano Gullá, T Scott Chen
1Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Abstract:
Interactions among Bcl-2 family proteins are important for regulating apoptosis. Prosurvival members of the family interact with proapoptotic BH3 (Bcl-2-homology-3)-only members, inhibiting execution of cell death through the mitochondrial pathway. Structurally, this interaction is mediated by binding of the alpha-helical BH3 region of the proapoptotic proteins to a conserved hydrophobic groove on the prosurvival proteins. Native BH3-only proteins exhibit selectivity in binding prosurvival members, as do small molecules that block these interactions. Understanding the sequence and structural basis of interaction specificity in this family is important, as it may allow the prediction of new Bcl-2 family associations and/or the design of new classes of selective inhibitors to serve as reagents or therapeutics. In this work, we used two complementary techniques--yeast surface display screening from combinatorial peptide libraries and SPOT peptide array analysis--to elucidate specificity determinants for binding to Bcl-x(L)versus Mcl-1, two prominent prosurvival proteins. We screened a randomized library and identified BH3 peptides that bound to either Mcl-1 or Bcl-x(L) selectively or to both with high affinity. The peptides competed with native ligands for binding into the conserved hydrophobic groove, as illustrated in detail by a crystal structure of a specific peptide bound to Mcl-1. Mcl-1-selective peptides from the screen were highly specific for binding Mcl-1 in preference to Bcl-x(L), Bcl-2, Bcl-w, and Bfl-1, whereas Bcl-x(L)-selective peptides showed some cross-interaction with related proteins Bcl-2 and Bcl-w. Mutational analyses using SPOT arrays revealed the effects of 170 point mutations made in the background of a peptide derived from the BH3 region of Bim, and a simple predictive model constructed using these data explained much of the specificity observed in our Mcl-1 versus Bcl-x(L) binders.
Insights
Researchers identified specific BH3 peptides that selectively bind to Mcl-1 or Bcl-x(L) proteins, crucial regulators of apoptosis. This work advances understanding of Bcl-2 family interactions and aids in designing targeted inhibitors.
Area of Science:
- Molecular Biology
- Structural Biology
- Drug Discovery
Background:
- Bcl-2 family proteins regulate apoptosis through interactions between prosurvival and proapoptotic members.
- Prosurvival proteins inhibit cell death by binding proapoptotic BH3-only proteins via a conserved hydrophobic groove.
- Understanding interaction specificity is key for developing selective inhibitors for therapeutic or research purposes.
Purpose of the Study:
- To elucidate the sequence and structural basis of binding specificity for Bcl-x(L) versus Mcl-1.
- To identify novel BH3 peptides with selective binding affinities for Mcl-1 or Bcl-x(L).
- To develop a predictive model for Bcl-2 family protein interactions.
Main Methods:
- Yeast surface display screening of combinatorial peptide libraries.
- SPOT peptide array analysis for mutational studies.
- X-ray crystallography to determine the binding mode of a peptide to Mcl-1.
Main Results:
- Identified BH3 peptides with selective or high-affinity binding to Mcl-1 and/or Bcl-x(L).
- Demonstrated peptide competition with native ligands for the conserved hydrophobic groove.
- Developed a predictive model explaining Mcl-1 versus Bcl-x(L) binding specificity based on mutational data.
Conclusions:
- BH3 peptide screening and analysis successfully identified determinants of Bcl-2 family binding specificity.
- The findings facilitate the design of selective inhibitors targeting Mcl-1 or Bcl-x(L).
- This study provides a foundation for predicting novel Bcl-2 family interactions and developing new therapeutics.

